You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone
  1. Kentaro Sugano
  1. Department of Medicine, Jichi Medical University, Shimotsuke, Japan
  1. Correspondence to: Kentaro Sugano
    Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan; sugano{at}jichi.ac.jp

https://doi.org/10.1136/ebmed-2012-100711

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379–86.OpenUrlCrossRefPubMed

    Context

    Non-steroidal anti-inflammatory drugs (NSAID) are widely prescribed worldwide. However, NSAID use frequently accompanies gastrointestinal (GI) injury including complications such as bleeding and perforation. Therefore co-therapy with gastroprotective drugs especially for those at risk has been advocated in current guidelines1 in which proton-pump inhibitors (PPI) and misoprostol are recommended to reduce NSAID-induced gastroduodenal ulcers. Another approach is to use cyclooxygenase-2 (COX-2) specific inhibitors.1 The role of histamine-2 receptor antagonists (H2RAs), however, remains uncertain in this regard. The only H2RA that …

    View Full Text

    Footnotes

    • Competing interests KS has received research grants from Takeda Pharmaceuticals, Eisai Pharmaceuticals, Astellas Pharmaceuticals and Astra-Zeneca Japan. He is also a consultant for Takeda Pharmaceuticals and Astra-Zeneca Japan and has received lecture fees from Takeda Pharmaceuticals.